MISSISSAUGA, ONTARIO--(CCNMatthews - June 5, 2006) - Covalon Technologies Ltd. ("Covalon") (TSX VENTURE:COV) has received notice that its patent application relating to drug-eluting, biodegradable tissue coverings has been published in the USA and for EU countries.

Medical devices that may benefit from this technology include a variety of configurations such as antimicrobial silver ion releasing and drug releasing wound dressings, implantable medical devices and wound closure systems to help reduce hospital acquired infection, and tissue and vascular coverings which release the drug Sirolimus, useful for helping to reduce neointimal hyperplasia.

The Covalon bioerodable polymer matrix is not restricted to a single type of therapeutic or antiseptic agent. The matrix composition is intended to comprise a variety of active agents, including cytostatic agents, such as Sirolimus, antibiotics, hormones, growth factors, anti-aging agents, immunosupressants, anesthetics and other factors that are beneficial for the medical condition under management.

The technology serves to augment Covalon's position in the expanding area of convergent medical devices.

Covalon Technologies Ltd. is a developer of advanced medical products which has patented therapeutic biomaterials for wound care and surgical applications and coatings for medical devices. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices. A variety of applications for this technology has been identified and specific products have been developed. These products feature solutions to many of the problems caused by the material properties of the medical devices currently offered by most manufacturers and suppliers, including infection, poor biocompatibility and microbial attachment.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.